REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF
1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left v...
24 Jun 20244min
Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study
The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF). In this...
22 Jun 20245min
AI in Cardiovascular Medicine: JACC Review
Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, e...
21 Jun 20246min
2024 ACC Peripheral Artery Disease (PAD) Guidelines
Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss....
31 Mai 20246min
2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy
2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten: Class 1 recommendation for symptomatic obstructive HCM. Exercise: Now allows for "vigorous" activity; competitive lev...
21 Mai 20249min
DOACs: When direct oral anticoagulants should not be used?
Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review sup...
29 Jan 20244min
Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)
Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptom...
22 Jan 20243min
